Adalimumab in ulcerative colitis – efficacy, safety and optimization in the era of treat-to target
Author:
Affiliation:
1. Inflammatory Bowel Disease Service, Department of Gastroenterology, The Alfred Hospital and Monash University, Melbourne, Australia
Publisher
Informa UK Limited
Subject
Clinical Biochemistry,Drug Discovery,Pharmacology
Link
https://www.tandfonline.com/doi/pdf/10.1080/14712598.2017.1309390
Reference64 articles.
1. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease.
2. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease.
3. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
4. Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial
5. Maintenance Therapy with Certolizumab Pegol for Crohn's Disease
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Phage Display as a Medium for Target Therapy Based Drug Discovery, Review and Update;Molecular Biotechnology;2024-06-01
2. High refill-adherence to adalimumab is associated with low disease activity in patients with inflammatory bowel disease;European Journal of Clinical Pharmacology;2024-03-30
3. Pathological mechanism and targeted drugs of ulcerative colitis: A review;Medicine;2023-09-15
4. Comparison of Two Clinical Laboratory Assays for Measuring Serum Adalimumab and Antibodies to Adalimumab;The Journal of Applied Laboratory Medicine;2023-09-02
5. Identifying Patients for Self-Administration of Omalizumab;Advances in Therapy;2022-09-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3